A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma Meeting Abstract
| Authors: | Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; Grieve, C.; Haskell, E.; Haydu, J. E.; Johnson, P. C.; Joseph, A.; Kelly, H. E.; Labarre, A.; Littlejohn, E. D.; Lue, J. K.; Mi, J.; Martignetti, R.; McCambridge, G.; Moskowitz, A.; Owens, C.; Plummer, S. F.; Puccio, M. G.; Salles, G.; Seshan, V.; Slupe, N.; Zelenetz, A. D. |
| Abstract Title: | A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 738 |
| Language: | English |
| ACCESSION: | WOS:001159306703007 |
| DOI: | 10.1182/blood-2023-180069 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
